nanopore technology for the molecular diagnostics of the future (nanodiag BW)

© Hahn-Schickard

The Clusters4Future network nanodiag BW brings together multidisciplinary research results that are on the threshold of application and develops them into a generic platform that enables powerful diagnosis.

Nanopore technology for a better health care

By translating nanopore technology into innovative products and services, nanodiag BW is making an important contribution to early detection and more targeted treatment of common epigenetic diseases such as cancer, diabetes, cardiovascular and infectious diseases.

The cluster aims to decisively promote medical progress through new, personalised diagnostic systems with high exploitation potential and to establish them sustainably in Germany. The synergies of the open innovation network favour the establishment of international lead providers for innovative nanopore technologies. This gives Germany a global competitive advantage as a centre of innovation in the health industry of the future.

Interaction between application-oriented and basic research

nanodiag BW enables groundbreaking innovation by combining application-oriented research fields such as epigenetics or microbiology with basic research in physics, biochemistry and physiology as well as the completely new possibilities of bioinformatics, molecular dynamic simulations, artificial intelligence (AI) and machine learning. Micro- and nanofluidics and microelectronics help to build integrated systems for users.

Clusters4Future – nanodiag BW selected for funding

The course for the emergence of nanodiag BW was set in November 2020 in the second round of the Clusters4Future competition called by the BMBF. nanodiag BW made it into the funded conception phase in September 2021 after a multi-stage selection process and was selected in July 2022 as one of seven clusters in the second round of the competition. Since April 2023, nanodiag BW has been in the funding of an initial three-year implementation phase.